1. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.

    Oncogene 35(27):3607 (2016) PMID 26500061 PMCID PMC4846581

    Human epidermal growth factor receptor-2 (HER2) amplification/overexpression (HER2+) frequently co-occurs with PI3K pathway activation in breast tumors. PI3K signaling is most often activated by PIK3CA mutation or PTEN loss, which frequently results in sensitivity to p110α or p110β inhibitors, r...
  2. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.

    Oncogene 35(23):2961 (2016) PMID 26640141 PMCID PMC4896860

    Human breast cancers that have HER2 amplification/overexpression frequently carry PIK3CA mutations, and are often associated with a worse prognosis. However, the role of PIK3CA mutations in the initiation and maintenance of these breast cancers remains elusive. In the present study, we generated...
  3. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

    Annals of Oncology 26(8):1533 (2015) PMID 25939896 PMCID PMC4511219

    The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as 'no ink on invasive tumor or DCIS' and the safety of omitti...
  4. Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

    British Journal of Cancer 111(8):1532 (2014) PMID 25101563 PMCID PMC4200088

    In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a t...
  5. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).

    Pharmacogenomics Journal 14(4):336 (2014) PMID 24513692 PMCID PMC4111770

    Peripheral neuropathy is a common dose-limiting toxicity for patients treated with paclitaxel. For most individuals, there are no known risk factors that predispose patients to the adverse event, and pathogenesis for paclitaxel-induced peripheral neuropathy is unknown. Determining whether there ...
  6. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

    Annals of Oncology 24(9):2206 (2013) PMID 23917950 PMCID PMC3755334

    The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refi...
  7. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.

    Breast Cancer Research and Treatment 140(2):331 (2013) PMID 23868188

    Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC...
  8. Attitudes of patients with metastatic breast cancer toward research biopsies.

    Annals of Oncology 24(7):1853 (2013) PMID 23493137

    Research studies involving human tissue are increasingly common. However, patients' attitudes toward research biopsies are not well characterized, particularly when the biopsies are carried out outside the context of therapeutic trials. One hundred sixty patients with metastatic breast cancer (M...
  9. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.

    Annals of Oncology 24(7):1841 (2013) PMID 23559151 PMCID PMC3690910

    A multicenter NCI-sponsored phase II study was conducted to analyze the safety and efficacy of the combination of ixabepilone with trastuzumab in patients with metastatic HER2-positive breast cancer. Two cohorts were enrolled: cohort 1 had received no prior chemotherapy or trastuzumab for metast...
  10. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.

    Annals of Oncology 24(6):1434 (2013) PMID 23425944

    The causes, optimal treatments, and medical/psychosocial sequelae of breast cancer in men are poorly understood. A systematic review of the English language literature was conducted to identify studies relevant to male breast cancer between 1987 and 2012 and including at least 20 patients. Searc...
  11. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.

    Breast Cancer Research and Treatment 139(2):403 (2013) PMID 23645007

    We aimed to evaluate the efficacy and feasibility of combining trastuzumab/vinorelbine with bevacizumab in patients with first-or second-line HER2-positive, metastatic breast cancer (MBC). Eligible patients had HER2-positive measureable MBC, with no more than one prior line of chemotherapy, and ...
  12. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

    Annals of Oncology 24(2):283 (2013) PMID 23022997 PMCID PMC3551479

    Human epidermal growth factor receptor-2 (HER2) overexpression occurs in ∼20% of breast cancers and has historically been associated with decreased survival. Despite substantial improvements in clinical outcomes, particularly with the emergence of HER2-targeted therapy, a substantial minority of...
  13. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).

    Annals of Oncology 23(12):3075 (2012) PMID 22767584 PMCID PMC3501229

    Cyclophosphamide-methotrexate-5-fluorouracil (CMF) is often selected as adjuvant chemotherapy for older patients with early-stage breast cancer due to perceived superior tolerability. We sought to measure persistence with CMF, adherence to oral cyclophosphamide, and the association of these with...
  14. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.

    Breast Cancer Research and Treatment 131(3):1061 (2012) PMID 22080245

    Prior studies have suggested a higher prevalence of high grade, ER-negative, HER2-positive, and basal-like carcinomas in young women with breast cancer. However, the precise distribution of poor prognostic features in this population remains unclear. We examined the pathologic features and distr...
  15. CMF revisited in the 21st century.

    Annals of Oncology 23(2):305 (2012) PMID 21715566

    Over the last 35 years, classical CMF (combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil) has been a milestone in the adjuvant treatment of women with breast cancer. However, after an early burst of success lasted just over 10 years, classical CMF has been supplanted ...
  16. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.

    Annals of Oncology 23(1):93 (2012) PMID 21531783 PMCID PMC3276325

    Women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) can respond to multiple lines of anti-HER2 therapy. It is unknown whether these patients will derive further clinical benefit following treatment with trastuzumab-MCC-DM1 (T-DM1). We retrospectivel...
  17. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?

    Annals of Surgical Oncology 18(3):733 (2011) PMID 20882415

    Neoadjuvant chemotherapy is being increasingly used in operable breast cancer. There are limited data on the safety of bevacizumab (bev) in the neoadjuvant setting. We sought to explore the safety of neoadjuvant cisplatin/bev in a protocol for triple negative breast cancer (TNBC). A total of 51 ...
  18. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.

    Breast Cancer Research and Treatment 117(3):615 (2009) PMID 19294501 PMCID PMC4578795

    This phase I study explored gefitinib (G) and capecitabine (C) in metastatic breast cancer (MBC). Sequential cohorts (n = 3) received G and escalating C on a 14 day on/7 day off schedule, with a validation cohort (n = 10) at the maximum tolerated dose (MTD). Dose limiting toxicity (DLT) was defi...
  19. The impact of sharing results of a randomized breast cancer clinical trial with study participants.

    Breast Cancer Research and Treatment 115(1):123 (2009) PMID 18543100

    There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group ...
  20. Menopausal-type symptoms in young breast cancer survivors.

    Annals of Oncology 17(12):1777 (2006) PMID 16971671

    There has been little previous information available about menopausal-type symptoms in very young breast cancer survivors. In collaboration with the Young Survival Coalition, we conducted an Internet-based survey of women with a history of breast cancer diagnosed at age 40 years or younger using...